What the FDA labels say about taking them together
Ensitrelvir and eplerenone
Ensitrelvir's FDA label of June 3, 2026 names eplerenone in its drug interactions section; the eplerenone label PlainMeds reads does not name ensitrelvir. The ensitrelvir label: “Co-administration is contraindicated.”
Check it at the source: the ensitrelvir FDA label on DailyMed (effective June 3, 2026, Shionogi Inc.); the eplerenone FDA label on DailyMed (effective June 23, 2025, Viatris Specialty LLC).
What does the ensitrelvir label say about eplerenone?
Ensitrelvir label, drug interactionsDrug Class: Cardiovascular drugs; Drug (s) within Class: eplerenone, ivabradine; Effect on Drug Concentration: ↑ eplerenone, ivabradine; Clinical Comment: Co-administration is contraindicated.
Source: FDA drug label (XOCOVA), Shionogi Inc., effective June 3, 2026 (SPL set 526acf60-abc3-2cc2-e063-6294a90affa6), via openFDA; the full label on DailyMed
What does the eplerenone label say about ensitrelvir?
Eplerenone's label (effective June 23, 2025) does not name ensitrelvir in these sections. A label lists what its studies and reports found; it is not a complete list.
Source: FDA drug label (Inspra), NDA021437 (Upjohn), as published by Viatris Specialty LLC, effective June 23, 2025 (SPL set 1a52bedc-8e2c-4116-a296-a87770676b4a), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Ensitrelvir | Eplerenone | |
|---|---|---|
| Labeled for | COVID-19 | Heart failure, High blood pressure |
| Boxed warning | No | No |
| Pharmacy cost (NADAC) | n/a | $0.308 per tablet 25 mg tablet |
| Shortage now | No current entry | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once